Investigation of mechanisms of pulmonary hypertension due to left heart disease

Investigation of mechanisms of pulmonary hypertension due to left heart disease - LHD-PH study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180123

Enrollment

100

Registered

2019-03-23

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure pulmonary hypertension

Interventions

A Rho-kinase inhibitor is administered over a period of 30 minutes during cardiac catheterization

vasodilation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart Failure due to left heart disease with NYHA classifications 2-4

Exclusion criteria

Exclusion criteria: 1. Severe primary valvular heart disease 2. Acute coronary syndrome 3. Cardiogenic shock 4. Mechanical ventilation 5. Pulmonary hypertension except for Group 2 6. Connective tissue disease 7. Stage 5 chronic kidney disease 8. Active Pneumonia 9. Life expectancy less than 1 year due to malignant disease 10. Pregnancy 11. Others not applicable person determined by a doctor

Design outcomes

Primary

Measure	Time frame
Changes in pulmonary vascular resistance in response to Fasudil administration in reactive pulmonary hypertension.	—

Secondary

Measure	Time frame
Changes in pulmonary vascular resistance in response to Fasudil administration in passive pulmonary hypertension. Changes in cardiac index in response to Fasudil administration in reactive and passive pulmonary hypertension. Changes in mean pulmonaryarterial pressure in response to Fasudil administration in reactive and passive pulmonary hypertension. Changes in cyclic GMP in response to Fasudil administration in reactive and passive pulmonary hypertension.	—

Measure

Time frame

Changes in pulmonary vascular resistance in response to Fasudil administration in passive pulmonary hypertension. Changes in cardiac index in response to Fasudil administration in reactive and passive pulmonary hypertension. Changes in mean pulmonaryarterial pressure in response to Fasudil administration in reactive and passive pulmonary hypertension. Changes in cyclic GMP in response to Fasudil administration in reactive and passive pulmonary hypertension.

—

Contacts

Public ContactKaoru Dohi

Mie University Hospital

dohik@clin.medic.mie-u.ac.jp+81-59-231-5015

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026